PF

Pfizer IncNYSE PFE Stock Report

Last reporting period 30 Jun, 2024

Updated 17 Sep, 2024

Last price

Market cap $B

170.4

Mega

Exchange

XNYS - New York Stock Exchange, Inc

PFE Stock Analysis

PF

Uncovered

Pfizer Inc is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

10/100

Low score

Market cap $B

170.4

Dividend yield

6.89 %

Shares outstanding

5 619.07 B

Pfizer Inc. is a research-based global biopharmaceutical company. The company is headquartered in New York City, New York and currently employs 83,000 full-time employees. The firm is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products around the world. The firm operations through two segments: Biopharma and PC1. Biopharma is a science-based medicines business that includes six therapeutic areas, such as Vaccines, Hospital, Oncology, Internal Medicine, Rare Disease, and Inflammation & Immunology. PC1 is its global contract development and manufacturing organization and supplier of specialty active pharmaceutical ingredients. Its Vaccines include Comirnaty/BNT162b2, the Prevnar family, Nimenrix and others. Its Oncology products include Ibrance, Xtandi, Inlyta, Sutent, Retacrit, Lorbrena and Braftovi. Its Internal Medicine products include Eliquis and the Premarin family. Its Inflammation & Immunology products include Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis and Cibinqo. The company also offers Rimegepant and Zavegepant.

View Section: Eyestock Rating